Title
Category
Credits
Event date
Cost
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
  • S.U.D
  • 0.50 AAFP Prescribed
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, participants should be able to:
  • S.U.D
  • Women's Health
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objectives:After this course, participants should be able to:
  • S.U.D
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • 0.50 AAFP Prescribed
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
  • 1.00 AAFP Prescribed
$0.00
Despite the successes demonstrated by Accountable Care Organizations (ACOs) over the last decade, health disparities remain a critical and ever-growing challenge. ACOs have the potential to advance health equity, but without intentionality and guardrails in place, they are also in a position to worsen existing health disparities. For ACOs to truly succeed in improving patient health outcomes for all, it's imperative that health equity is kept at the forefront of value-based care efforts. Learning Objective:At the end of this session, learners should be able to:
  • S.U.D
  • 1.00 AAFP Prescribed
$0.00
​Join Family Physician Rebecca Trotsky-Sirr and Sergeant Brian Gunsolley for a discussion of how patients are obtaining Fentanyl and other synthetic opioids and how physicians can help their patients recognize and understand the dangers of non-prescribed medication as well as encourage the use of reversal agents. In addition, resources will be provided to encourage more use of Medication Assisted Treatment.Learning Objectives:At the end of this session, learners should be able to:
  • Diabetes
  • 1.00 AAFP Prescribed
  • 1.00 AOA Category 2-A
$0.00
This interactive, case-based activity provides education on the clinical characteristics of the GLP-1 RAs, how they differ from each other, and the rationale and guidance for their use with patients with Type 2 Diabetes (T2D). Participants will encounter clinical case scenarios on personalizing treatment with GLP-1 RAs, taking into account patient characteristics and preferences, adherence, and management of side effects.Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • 1.25 AAFP Prescribed
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • Pain Management
  • 3.00 AAFP Prescribed
  • 3.00 AMA PRA Category 1 Credit™
$0.00
The curriculum, Pain Management and Opioids: Balancing Risks and Benefits, meets the latest FDA Blueprint and CDC guidelines for opioid prescribing and pain management, and includes the impact of COVID-19, new pain relieving treatments, and telehealth. This education includes California state-specific information and counts towards California CME requirements for pain management and opioid prescribing practices.This activity meets the new DEA CME requirement when renewing or obtaining your DEA license.

Pages